Government of Nova Scotia Report issue

Government Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2008
NCT00833300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cynthia Calkin | Department of Health, Nova Scotia | Jaclyn Tran | K. Sue Robinson | Lisa Barrett | Mary Lynch | Michael Bezuhly | Richard Hall | Ross K Leighton MD FRCSC | Staff surgeon (ophthalmic plastic and reconstructive surgery)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 4)

Bipolar Disorder (Phase 3)

Blood Coagulation Disorders (Phase 4)

Constipation (Phase 4)

Coronavirus Infections (Phase 2)

Hemostatic Disorders (Phase 4)

Hepatitis C (Phase 4)

Insulin Resistance (Phase 3)

Menorrhagia (Phase 4)

Neuralgia (Phase 3)

Thromboembolism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 21